DOI: 10.4103/jcrt.jcrt_1982_22 ISSN: 0973-1482

An up-to-date view of paclitaxel-induced peripheral neuropathy

Shan Wu, Tu Xiong, Shenglan Guo, Cuiyi Zhu, Jing He, Shurong Wang
  • Radiology, Nuclear Medicine and imaging
  • Oncology
  • General Medicine

Chemotherapy-induced peripheral neuropathy (CIPN),referring to the damage to the peripheral nerves caused by exposure to a neurotoxic chemotherapeutic agent, is a common side effect amongst patients undergoing chemotherapy. Paclitaxel-induced peripheral neuropathy (PIPN) can lead to dose reduction or early cessation of chemotherapy, which is not conducive to patients’survival. Even after treatment is discontinued, PIPN symptoms carried a greater risk of worsening and plagued the patient’s life, leading to long-term morbidity in survivors. Here, we summarize the research progress for clinical manifestations, risk factors, pathogenesis, prevention and treatment of PIPN, so as to embark on the path of preventing PIPN with prolongation of patient’s life quality on a long-term basis.

More from our Archive